JPRN-jRCT2080223643已完成3 期
Phase 3 Study to Assess the Long-Term Safety and Efficacy of JTZ-951 in Anemic Patients with Chronic Kidney Disease Not Requiring Dialysis <Long-Term Study> (SYMPHONY ND-Long)
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 132
研究概览
简要总结
SYMPHONY ND-Long confirmed that no major safety issue was indentified for 52-week treatment with JTZ-951. The efficacy is maintained during the whole treatment period.
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •ESA naive patients:
- •Hemoglobin level of => 8.0 g/dL and =< 10.5 g/dL
- •ESA treated patients:
- •Hemoglobin level of => 9.0 g/dL and =< 12.0 g/d
排除标准
- •Patients with poorly controlled hypertension
- •Patients with congestive heart failure or unstable angina
- •Patients with malignancy
研究者
相似试验
已完成
3 期
Phase 3 Long-Term Study of JTZ-951 in Anemic Patients with Chronic Kidney Disease Receiving Maintenance Hemodialysis (SYMPHONY HD-Long)Anemia with CKDJPRN-jRCT2080223644Japan Tobacco Inc.136
已完成
3 期
"A Long-Term Safety Study of JZP-110 in the Treatment of Excessive Sleepiness in Subjects With Narcolepsy or OSA"NarcolepsyObstructive Sleep ApneaNCT02348632Jazz Pharmaceuticals645
进行中（未招募）
1 期
Study to evaluate the long term safety, tolerability, and durability of treatment effect of ALKS 3831 in subjects with schizophrenia, schizophreniform disorder, or bipolar I disorder.EUCTR2017-000918-36-GBAlkermes Inc500
进行中（未招募）
1 期
Study to evaluate the long term safety, tolerability, and durability of treatment effect of ALKS 3831 in subjects with schizophrenia, schizophreniform disorder, or bipolar I disorder.EUCTR2017-000918-36-IEAlkermes Inc500
进行中（未招募）
1 期
Study to evaluate the long term safety, tolerability, and durability of treatment effect of ALKS 3831 in subjects with schizophrenia, schizophreniform disorder, or bipolar I disorder.EUCTR2017-000918-36-ATAlkermes Inc500